Welcome to the Translational Research Networking and Preclinical Models (TRNPM) website!
The purpose of the Translational Research Networking and Preclinical Models (TRNPM) Shared Resource is to provide a nexus for multiple aspects of translational immunology research. The TRNPM enables and promotes collaboration among investigators along the continuum of basic-translational-clinical research by establishing mechanisms that facilitate availability of human tissue for research and by generating and maintaining preclinical mouse models for the development and testing of candidate therapeutics.
Access to human tissue of immunological relevance
To succeed in the development of novel therapies, investigators need to access primary human cells and tissues that are healthy or affected by inflammation, cancer and autoimmunity, which is challenging for non-clinicians. Tissue studies from healthy control, preclinical and clinical subjects are required to fully understand the immunological impact of various therapeutic interventions, and ultimately bridge the gap to clinical care delivery. The TRNPM will establish a network of clinicians, clinician/scientists and basic investigators to facilitate collaborative studies on primary human tissue of immunological relevance.
Access to humanized mice, hu-mice
Novel immunotherapies must be tested with sophisticated preclinical models before they can be tried in humans. Ideally, these models should provide a platform where the human immune system can be exposed to experimental and therapeutic manipulations and the readout is meaningful and applicable to humans.
The TRNPM will provide this key component with the production, distribution and/or analysis of humanized mice. Humanized mice are immunodeficient mice transplanted with a human immune system, or some of its components. When humanized mice are engrafted with tumors, they become an ideal tool for testing the effects of novel immunotherapies—such as immune checkpoint inhibitors—on human immune responses.
While more often used in the immune-oncology arena, humanized mice can also be utilized to understand basic mechanisms of the human immune system and to study genetic, biological, and pharmacological therapies to autoimmune and inflammatory responses. The laboratory directed by Dr. Roberta Pelanda has spent the last 10 years developing and improving humanized mice for the study of B cells in the context of autoimmunity. In the last 2 years, the laboratory has also been involved in using humanized mice to study the effects of drugs on the immune response to tumors.
Additional humanized mouse models are under development that will expand current capabilities. Examples are the production of humanized mice with either bone marrow (CD34-BM-BRGS hu-mice) or mobilized peripheral blood for the purpose of immune-oncology studies with matching immune system and tumor, or with the transplantation of fetal liver cells and thymus (CD34-FLT-BRGS hu-mice) for the purpose of infection, vaccine or tumor studies.
Access to experimental design support and research-related services
The TRNPM team offers expert experimental design support on projects, assistance in a variety of research needs within projects (e.g. antibody panel design for flow cytometric analyses, isolation and processing of cells from humanized mice, cell staining, sample runs on the flow cytometer, analysis of flow data) and integration with the HIMSR for additional analyses (e.g. Vectra, CyTOF, etc.).
Please contact us (Roberta.Pelanda@ucdenver.edu or Julie.Lang@ucdenver.edu) if interested in learning more about our experimental design support services, research services, access to human tissue or humanized mice.
We look forward to hearing from you!